{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:12:45Z","timestamp":1783930365488,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives:\u00a0Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic GLA gene variants, leading to progressive multi-organ damage including end-stage renal disease. Although dialysis patients represent a high-risk population for undiagnosed FD, data from T\u00fcrkiye using genetic analysis as the primary screening method remain limited. This study aimed to determine FD prevalence among hemodialysis patients across multiple centers in T\u00fcrkiye and to perform cascade family screening of confirmed cases. Materials and Methods:\u00a0This multicenter cross-sectional study screened 1359 adult hemodialysis patients across 8 centers in Ankara, T\u00fcrkiye, using complete GLA gene sequencing. Variants were classified per American College of Medical Genetics and Genomics criteria. Patients with pathogenic variants underwent confirmatory biochemical testing (\u03b1-galactosidase A activity and plasma lyso-Gb3). Cascade screening was performed for confirmed index cases. Results:\u00a0Among 1359 patients (mean age 62.3 \u00b1 14.3 years; 38.5% female), GLA variants were identified in 12 (0.88%): 8 benign\/likely benign (including 7 p.D313Y pseudodeficiency alleles), 2 unclassified variants, 1 variant of uncertain significance, and 1 confirmed classic FD (prevalence: 0.07%; 95% CI: 0.002\u20130.41%). Cascade screening of the index patient identified 6 carriers among 10 relatives tested (60% yield). Three of 7 carriers (43%) were initiated on enzyme replacement therapy. Conclusions:\u00a0Among 1359 hemodialysis patients, GLA gene sequencing identified 12 variants (0.88%), yet only one was confirmed as a disease-causing mutation responsible for end-stage renal disease (prevalence: 0.07%). The remaining variants comprised polymorphisms, likely benign pseudodeficiency alleles and variants of uncertain significance; most of which would not have been detected by enzyme-based screening alone, as enzyme activity was normal in these carriers. Cascade screening of the single confirmed index case yielded 6 carriers among 10 relatives tested (60%), including one hemizygous male with classic FD on hemodialysis, and three carriers were initiated on enzyme replacement therapy. These findings demonstrate that GLA gene analysis is a valuable instrument for screening in dialysis populations, as it captures the full variant spectrum while enabling rigorous distinction between the overall GLA variant carrier rate and the true disease prevalence defined by variants causing end-stage renal disease. Future screening studies should report prevalence based exclusively on confirmed disease-causing variants rather than total variant counts, which have inflated prevalence estimates in prior literature.<\/jats:p>","DOI":"10.3390\/medicina62071343","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:28:27Z","timestamp":1783927707000},"page":"1343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening for Fabry Disease Among Dialysis Patients: A Multicenter Cross-Sectional Study in T\u00fcrkiye with Cascade Screening of Identified Cases"],"prefix":"10.3390","volume":"62","author":[{"given":"Kadir G\u00f6khan","family":"At\u0131lgan","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-900X","authenticated-orcid":false,"given":"Berrak It\u0131r","family":"Ayl\u0131","sequence":"additional","affiliation":[{"name":"School of Life Sceinces, University of Westminster, London W1B 2HW, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Deniz","family":"Ayl\u0131","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","unstructured":"Valle, D.L., Antonarakis, S., Ballamio, A., Beaudet, A.L., and Mitchell, G.A. (2001). \u03b1-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill. [8th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: A systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry Disease: Prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017","volume":"55","author":"Doheny","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"107714","DOI":"10.1016\/j.ymgme.2023.107714","article-title":"Prevalence of Fabry disease in patients with chronic kidney disease: A systematic review and meta-analysis","volume":"140","author":"Linares","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s10038-019-0633-1","article-title":"High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations","volume":"64","author":"Nakagawa","year":"2019","journal-title":"J. Hum. Genet."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.15537\/smj.2020.8.25184","article-title":"Screening for Fabry disease among 619 hemodialysis patients in Saudi Arabia","volume":"41","author":"Alhemyadi","year":"2020","journal-title":"Saudi Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ng, K.P., Sandhu, M., Banerjee, D., Burton, J., Crowley, L., Doulton, T., Hameed, M., Hamer, R., Menon, M., and Nicholas, J. (2025). Fabry disease in the haemodialysis population: Outcome of a UK screening study (SoFAH). BMC Nephrol., 26.","DOI":"10.1186\/s12882-025-04127-x"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nephro.2021.03.002","article-title":"Screening for Fabry disease in male patients with end-stage renal disease in western France","volume":"17","author":"Vigneau","year":"2021","journal-title":"Nephrol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2454295","DOI":"10.1080\/0886022X.2025.2454295","article-title":"Expanded screening for Fabry disease in patients with chronic kidney disease not on dialysis: A multicenter Italian experience","volume":"47","author":"Battaglia","year":"2025","journal-title":"Ren. Fail."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/1744-9987.13834","article-title":"Screening for Fabry disease among male patients on hemodialysis in Awaji Island","volume":"26","author":"Shimizu","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gene.2013.05.050","article-title":"Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: Identification of new case with novel mutation","volume":"527","author":"Okur","year":"2013","journal-title":"Gene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5414\/CN108672","article-title":"Prevalence of Fabry disease among Turkish dialysis patients: Data from hemodialysis centers in Bursa province","volume":"85","author":"Sayilar","year":"2016","journal-title":"Clin. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1159\/000452605","article-title":"The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study","volume":"41","author":"Turkmen","year":"2016","journal-title":"Kidney Blood Press. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/0886022X.2016.1254656","article-title":"Screening Fabry\u2019s disease in chronic kidney disease patients not on dialysis: A multicenter study","volume":"39","author":"Akdam","year":"2017","journal-title":"Ren. Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000496620","article-title":"Fabry Disease Prevalence in Renal Replacement Therapy in Turkey","volume":"142","author":"Eren","year":"2019","journal-title":"Nephron"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s11255-023-03488-2","article-title":"The prevalence of Fabry disease in a Turkish population with chronic kidney patients","volume":"55","author":"Tomar","year":"2023","journal-title":"Int. Urol. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13023-022-02215-x","article-title":"Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: A multidisciplinary Turkey perspective","volume":"17","author":"Ezgu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_24","first-page":"1561","article-title":"Is Fabry disease more prevalent than we think? Understanding the critical role of family screening can make all the difference","volume":"58","author":"Ozbek","year":"2026","journal-title":"Int. Urol. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","article-title":"Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease","volume":"101","author":"Germain","year":"2022","journal-title":"Clin. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: Characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum. Mutat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/8904_2012_154","article-title":"Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease","volume":"Volume 7","author":"Niemann","year":"2013","journal-title":"JIMD Reports\u2014Case and Research Reports, 2012\/4"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","article-title":"Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma","volume":"80","author":"Froissart","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e017098","DOI":"10.1136\/bmjopen-2017-017098","article-title":"Fabry disease due to D313Y and novel GLA mutations","volume":"7","author":"Koulousios","year":"2017","journal-title":"BMJ Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e004252","DOI":"10.1161\/CIRCGEN.123.004252","article-title":"Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies","volume":"16","author":"Monda","year":"2023","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1912","DOI":"10.1002\/mgg3.1912","article-title":"Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)","volume":"10","author":"Lau","year":"2022","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_33","first-page":"101029","article-title":"In vitro characterization of cells derived from a patient with the GLA variant c.376A>G (p.S126G) highlights a non-pathogenic role in Fabry disease","volume":"38","author":"Breyer","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1159\/000492593","article-title":"Systematic DNA Study for Fabry Disease in the End Stage Renal Disease Patients from a Southern Italy Area","volume":"43","author":"Zizzo","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrg775","article-title":"Listening to silence and understanding nonsense: Exonic mutations that affect splicing","volume":"3","author":"Cartegni","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"ref_36","unstructured":"National Center for Biotechnology Information (NCBI) (2026, February 25). NM_000169.3(GLA):c.352C>T (p.Arg118Cys) and Fabry Disease, Available online: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/RCV000078277\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_38","unstructured":"National Center for Biotechnology Information (NCBI) (2026, June 01). NM_000169.3(GLA):c.1093_1101dup (p.Ile367_Ala368insTyrThrIle) and Fabry Disease, Available online: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/4087244\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/ejhg.2011.87","article-title":"Fabry or not Fabry\u2014A question of ascertainment","volume":"19","author":"Houge","year":"2011","journal-title":"Eur. J. Hum. Genet."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1343\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:56:57Z","timestamp":1783929417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071343"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071343","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}